IMMUNOCORE HLDGS ADS/1 (6YG) — Cash Flow Reinvestment Rate
IMMUNOCORE HLDGS ADS/1 (6YG) has a Cash Flow Reinvestment Rate of 1.17x as of June 2025, reinvesting €30.41 Million (capex €414.00K plus investments €-30.00 Million) from operating cash flow of €25.96 Million. Check IMMUNOCORE HLDGS ADS/1 earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
IMMUNOCORE HLDGS ADS/1 Cash Flow Reinvestment Rate (2023–2024)
Historical reinvestment intensity for IMMUNOCORE HLDGS ADS/1 across 2 annual periods. Explore investment intensity of IMMUNOCORE HLDGS ADS/1 to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for IMMUNOCORE HLDGS ADS/1 (2023–2024)
Year-by-year capital reinvestment analysis for IMMUNOCORE HLDGS ADS/1. For live market cap and broader valuation context, see how much is IMMUNOCORE HLDGS ADS/1 worth.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 13.63x | €355.17 Million | €26.06 Million | €5.17 Million | ▲ +638.6% |
| 2023 | 1.85x | €5.42 Million | €2.94 Million | €5.42 Million | — |